t
ValiRx PLC issued a Director Disclosure Update on March 21, 2025, concerning its Chairman, Martin Gouldstone. This update disclosed that Oncimmune Holdings PLC, a company where Martin Gouldstone is also a Director, recently announced its intention to appoint administrators.
| Date | 21 Mar 2025 |
| Time | 11:07:30 |
| Category | Miscellaneous |
| ID | 6998B |
ValiRx PLC
("ValiRx" or the "Company")
Director Disclosure Update
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, issues the following disclosure in relation to Martin Gouldstone, Chairman of the Company pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Oncimmune Holdings PLC, a company which Martin Gouldstone is a Director, recently announced its intention to appoint administrators.
There is nothing further to disclose in respect of Schedule 2(g) of the AIM Rules for Companies.
The Directors of the Company take responsibility for this announcement.
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
https://valirx.com/link/oPB60P
|
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 115 784 0025
|
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
|
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
|
+44 (0) 115 787 0206
|
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com